N2-(1H-Benzo[d]imidazol-6-yl)-N4-cyclopropyl-5-(trifluoromethyl)pyrimidine-2,4-diamine

ID: ALA4741912

PubChem CID: 118905943

Max Phase: Preclinical

Molecular Formula: C15H13F3N6

Molecular Weight: 334.31

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  FC(F)(F)c1cnc(Nc2ccc3nc[nH]c3c2)nc1NC1CC1

Standard InChI:  InChI=1S/C15H13F3N6/c16-15(17,18)10-6-19-14(24-13(10)22-8-1-2-8)23-9-3-4-11-12(5-9)21-7-20-11/h3-8H,1-2H2,(H,20,21)(H2,19,22,23,24)

Standard InChI Key:  HTSMUTPVZNMYSW-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 27  0  0  0  0  0  0  0  0999 V2000
   19.8423   -2.3814    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.8412   -3.2009    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.5492   -3.6099    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.2589   -3.2004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2560   -2.3778    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.5474   -1.9725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1345   -1.9729    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1343   -1.1558    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   18.4269   -2.3817    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   18.4239   -1.5642    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   19.1331   -3.6089    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.9672   -3.6079    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   21.9685   -4.4251    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2601   -4.8333    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.2611   -5.6497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6749   -4.8288    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.1325   -4.4261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.7242   -5.1358    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.5414   -5.1364    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.6833   -5.6420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.9725   -6.0607    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1510   -6.8662    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.9722   -6.9453    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.3011   -6.1888    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  1  7  1  0
  7  8  1  0
  7  9  1  0
  7 10  1  0
  2 11  1  0
  4 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 21  2  0
 20 16  2  0
 16 13  1  0
 11 17  1  0
 18 17  1  0
 19 18  1  0
 17 19  1  0
 20 21  1  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 20  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4741912

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 334.31

Molecular Weight (Monoisotopic): 334.1154

AlogP: 3.69

#Rotatable Bonds: 4

Polar Surface Area: 78.52

Molecular Species: NEUTRAL

HBA: 5

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.34

CX Basic pKa: 6.29

CX LogP: 2.87

CX LogD: 2.84

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.68

Np Likeness Score: -1.61

References

1. Ren H,Bakas NA,Vamos M,Chaikuad A,Limpert AS,Wimer CD,Brun SN,Lambert LJ,Tautz L,Celeridad M,Sheffler DJ,Knapp S,Shaw RJ,Cosford NDP.  (2020)  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.,  63  (23): [PMID:33200929] [10.1021/acs.jmedchem.0c00873]

Source

Source(1):

• Scientific Literature